Agilent Technologies, Inc. (NYSE:A) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts also recently issued research reports about the company. Jefferies Group LLC reissued a “buy” rating and issued a $66.00 price target on shares of Agilent Technologies in a report on Wednesday. Barclays PLC reaffirmed a “buy” rating and set a $67.00 target price on shares of Agilent Technologies in a report on Wednesday, July 19th. Deutsche Bank AG reaffirmed a “buy” rating and set a $66.00 target price on shares of Agilent Technologies in a report on Thursday, June 22nd. BTIG Research lifted their target price on Agilent Technologies from $57.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, May 24th. Finally, Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 target price for the company in a report on Tuesday, May 16th. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Agilent Technologies currently has an average rating of “Buy” and a consensus target price of $60.12.

Shares of Agilent Technologies (NYSE A) traded up 1.30% during trading on Friday, reaching $59.33. The company’s stock had a trading volume of 1,511,552 shares. The firm’s 50-day moving average is $60.10 and its 200-day moving average is $55.69. Agilent Technologies has a 12-month low of $42.92 and a 12-month high of $61.84. The stock has a market capitalization of $19.06 billion, a PE ratio of 33.35 and a beta of 1.30.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, May 22nd. The medical research company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.10. The business had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.05 billion. Agilent Technologies had a return on equity of 16.49% and a net margin of 13.41%. The company’s quarterly revenue was up 8.1% on a year-over-year basis. During the same quarter last year, the company earned $0.44 earnings per share. Equities analysts expect that Agilent Technologies will post $2.23 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Agilent Technologies, Inc. (A) Cut to Buy at BidaskClub” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/12/agilent-technologies-inc-a-cut-to-buy-at-bidaskclub.html.

In other news, CFO Didier Hirsch sold 5,710 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $60.60, for a total value of $346,026.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael R. Mcmullen sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $59.86, for a total value of $2,993,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 112,608 shares of company stock valued at $6,737,509.

Several hedge funds have recently bought and sold shares of A. Cribstone Capital Management LLC boosted its stake in Agilent Technologies by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 2,359 shares of the medical research company’s stock worth $125,000 after buying an additional 54 shares during the period. Acrospire Investment Management LLC boosted its stake in Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock worth $148,000 after buying an additional 1,200 shares during the period. Parallel Advisors LLC boosted its stake in Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock worth $157,000 after buying an additional 131 shares during the period. Trust Co. of Vermont boosted its stake in Agilent Technologies by 8.1% in the first quarter. Trust Co. of Vermont now owns 2,743 shares of the medical research company’s stock worth $145,000 after buying an additional 205 shares during the period. Finally, CENTRAL TRUST Co boosted its stake in Agilent Technologies by 15.3% in the first quarter. CENTRAL TRUST Co now owns 2,994 shares of the medical research company’s stock worth $158,000 after buying an additional 398 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.